Willis, Mark  ORCID: https://orcid.org/0000-0003-3024-6063, Harding, Katharine, Pickersgill, T., Wardle, Mark, Pearson, O., Scolding, N., Smee, J. and Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909
2016.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Multiple Sclerosis Journal
22
(9)
, pp. 1215-1223.
10.1177/1352458515614092
|
Preview |
PDF
- Accepted Post-Print Version
Download (386kB) | Preview |
Abstract
Background: Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear understanding of its application and durability of effect in clinical practice has yet to evolve. Objectives: To investigate long-term efficacy and safety outcomes in a multicentre cohort of patients treated with alemtuzumab. Methods: Patients treated from 2000 and followed-up at three regional centres were identified. Baseline and prospective data were obtained and validated by clinical record review. Results: One hundred patients were identified with a mean follow-up of 6.1 years (range 1–13). Forty patients were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change in EDSS score was +0.14. Forty-seven patients developed secondary autoimmunity. Conclusion: Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of patients required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine Research Institutes & Centres > MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry |
| Publisher: | Sage |
| ISSN: | 1352-4585 |
| Date of First Compliant Deposit: | 8 March 2018 |
| Date of Acceptance: | 1 October 2015 |
| Last Modified: | 25 Nov 2024 10:30 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/87147 |
Citation Data
Cited 76 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric